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Using the National Institutes of Health (NIH) consensus criteria for chronic graft-versus-host disease (cGVHD),
we assessed the prevalence, symptoms, and clinical signs of female genital cGVHD in a cross-sectional
population-based study. Forty-two women were evaluated at a median of 80 months (range, 13 to 148
months) after undergoing hematopoietic stem cell transplantation (HSCT). Medical history, ongoing medi-
cations, and genital signs and symptoms were recorded. Gynecologic examination for the diagnosis and
clinical scoring of genital cGVHD was combined with clinical scoring of extragenital cGVHD for the estimation
of each patient’s global cGVHD score. Biopsy specimens from the genital mucosa were obtained from 38
patients. Genital cGVHD was diagnosed in 22 of 42 patients (52%). Its presence was associated with systemic
corticoid steroid treatment of extragenital cGVHD (P ¼ .001), older age (P ¼ .07), and HSCT from a sibling
donor (P ¼ .002). Five patients had isolated genital cGVHD. Dryness, pain, smarting pain (P < .05 for all), and
dyspareunia (P ¼ .001) were observed more frequently in the women with genital cGVHD. Twelve
patients had advanced genital cGVHD (clinical score 3), which was the main factor explaining the high
rate (15 of 42) of severe global cGVHD. The rate of genital cGVHD was similar (P ¼ .37) in patients with a
follow-up of 80 months (10 of 22) and those with a follow-up of <80 months (12 of 20). We found no
convincing relationship between clinical diagnosis and histopathological assessment of mucosal biopsy
specimens. In our group of women with a long follow-up after HSCT, genital cGVHD was common and in
many cases incorrectly diagnosed. Genital cGVHD causes genital symptoms and affects sexual life, and may
present without any other cGVHD, warranting early and continuous gynecologic surveillance in all women
after HSCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION The National Institutes of Health (NIH) Consensus
Chronic graft-versus-host disease (cGVHD) is the major
cause of late morbidity and nonrelapse mortality after allo-
geneic hematopoietic stem cell transplantation (HSCT) [1].
The pathophysiology of cGVHD is largely unknown, but
typical symptoms include inﬂammation and ﬁbrosis in oral,
ocular, and genital mucosal membranes. Chronic GVHD is
associated with diminished quality of life [2], and immuno-
suppressive therapy, mainly corticosteroids, increases the
risk of opportunistic infections. Compared with bone
marrow, the use of peripheral blood stem cells for HSCT is
associated with an increased incidence and severity of
cGVHD [3,4], and the incidence of symptomatic cGVHD
requiring medication is 40% to 70% [5].edgments on page 811.
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2014 American Society for Blood and Marrow
14.02.016Development Program proposed criteria for the diagnosis
and severity of signs and symptoms of organ-speciﬁc cGVHD,
including an algorithm for calculation of global severity
(mild, moderate, or severe) [6]. This classiﬁcation scheme has
been applied in several previous studies [2,7,8].
It is well recognized that cGVHD can affect the genitals,
and that female genital cGVHD is associated with sexual
dysfunction and genital symptoms, including dryness, ul-
cerations, and vaginal stenosis [9-13]. The estimated inci-
dence of female genital cGVHD varies owing to different
diagnostic criteria and/or selection criteria for inclusion of
patients into the different studies. As recently noted by
Hirsch et al. [13], there are reasons to assume that genital
cGVHD is an underdiagnosed and overlooked aspect of
cGVHD.
To assess the prevalence, symptomatology, and clinical
features of genital cGVHD, we performed a cross-sectional
study in a consecutive population-based cohort of women
in the western region of Sweden with a median follow-up of
80 months after HSCT. To elucidate a relationship between
clinical ﬁndings and histopathological diagnosis, biopsyTransplantation.
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areas were obtained from the vagina and/or vulva in the
majority of patients.
PATIENTS AND METHODS
Patients
A total of 86 women underwent HSCT between 1996 and November
2005 in the western region of Sweden, which has approximately 1.5 million
inhabitants. Fifty surviving female patients in complete remission were
identiﬁed. Of these 50 women, 3 were not invited to participate owing to
mental disability, 2 declined to participate, and 3 could not be treated with
local estrogen and thus were excluded. In all, 42 women gave written
informed consent at enrollment. The study was approved by the Regional
Ethical Review Board of Gothenburg.
Before study enrollment, most of the patients had been in regular or
sporadic contact with a gynecologist. Ten patients had been diagnosed with
cGVHD before study entry. Six patients had undergone surgery for vaginal
stenosis before study entry; 3 of these patients did not receive adequate
treatment for cGVHD and subsequently relapsed. All 42 patients were in
menopause (11 natural and 31 premature after HSCT).
Methods
All patients underwent HSCT and were followed as outpatients at the
Section of Hematology, Sahlgrenska University Hospital, Göteborg, Sweden.
Table 1 summarizes background factors and HSCT procedures. All patients
with an unrelated donor received antithymocyte globulin as part of the
conditioning regimen. For this study, patients were also seen at the
Department of Gynecology, NU Hospital Group, Trollhättan, Sweden by 1 or
2 gynecologists (E.S.K. and/or A.-K.B.). Before the ﬁrst visit, each patient
completed a comprehensive questionnaire on general medical history,
ongoing medication, and symptoms suggestive of any genital malfunction.
The questionnaire was adapted from a document produced by the Vulva
Group of the Swedish Society of Obstetrics and Gynecology for females with
vulvovaginal problems. All patients were seen at least twice.
To ensure that estrogen deﬁciency was not be mistaken for genital
cGVHD, all women with atrophic genital mucosa (n ¼ 26) at their ﬁrst visit
were prescribed local estrogen treatment for at least 6 weeks before the
second visit. In these women, ﬁnal diagnosis and scoring of clinical signs and
symptoms were done at the second visit. Supplemental local estrogen
therapy given at the ﬁrst visit to women with signs of hormone deﬁciency
did not affect diagnostic and distinctive signs of genital cGVHD.
Gynecologic examination with detailed structured documentation of
vulvovaginal signs was performed in all women. Photographic documen-
tation of the vulva was obtained at most visits, and information on ongoing
local or systemic immunosuppressive treatment was recorded.
Clinical Diagnosis of Genital cGVHD
For the diagnosis of genital cGVHD, the NIH consensus criteria were
applied based solely on genital signs. Vaginal synechia or scarring, partial or
total stenosis, and marked lichen planuselike features, such as reticular
white lines in the genital mucosa, were considered diagnostic of cGVHD.
Distinctive signs of genital cGVHD (eg, erosions, ﬁssures, ulcers) togetherTable 1
Clinical Characteristics of Patients with and without Genital cGVHD in a Cross-Sec
Characteristic All Patients (n ¼ 42)
Patients and diagnosis
Age at HSCT, yr, median (range) 39 (19-68)
Acute leukemias, n 21
Other, ny 21
Transplantation
Time after HSCT, mo, median (range) 80 (13-148)
Time between HSCT and GynDx <80/80 mo, n 20/22
Previous acute GVHD, yes/no, n 26/16
Donor, sibling/unrelated, n 19/23
Donor sex, female/male, n 17/25
Stem cell source, BM/PBSC, n 12/30
Conditioning, reduced/full intensity, n 13/29
Total body irradiation, yes/no, n 19/23
Systemic cGVHD
Systemic corticosteroid treatment, yes/no, n 15/27
Extragenital cGVHD, yes/no, n 26/16
GynDx indicates date of diagnostic visit; BM, bone marrow; PBSC peripheral blood
* Differences between patients with genital cGVHD and those without genital c
y Chronic myelogenous leukemia, n ¼ 17; myeloma, n ¼ 1; myelodysplastic synwith concurrent extragenital organ involvement were sufﬁcient for a diag-
nosis of cGVHD.
Symptoms
With the aim of getting a broad view of the patients’ discomfort, the
questionnaire inquired about 12 symptoms associated with genital
dysfunction, including itching, smarting pain, swelling, pain (with and
without touching), blisters, ﬁssures/wounds, dryness, discharge, vaginal
and/or vulvar constriction, and dyspareunia. The patients rated the fre-
quency of each symptom as 0, never; 1, seldom; 2, sometimes; 3, often; or 4,
always.
Clinical Scoring of Genital cGVHD
For evaluation of the functional status of cGVHD affected genital organs,
patients’ clinical signs and reported symptoms on coitus and/or at gyneco-
logic examination were combined and scored according to NIH criteria [6].
According to these criteria, 0 represents no symptoms; 1, symptoms, mild
signs on physical examination, no effect on coitus, and minimal discomfort
on gynecologic examination; 2, symptoms, moderate signs on examination,
and mild dyspareunia or discomfort on gynecologic examination; 3, symp-
toms, advanced signs, and severe pain with coitus or inability to insert a
vaginal speculum. If signs and symptoms diverged, symptoms were used for
scoring, and consequently asymptomatic patients were scored as 0 irre-
spective of signs.
Global Scoring of cGVHD
Global scoring of cGVHD according to the NIH criteria is based on the
number of organs involved and the clinical scoring of each affected organ,
with the aim of characterizing the clinical impact of cGVHD on the in-
dividual’s total functional status. For this study, data on the occurrence and
severity of extragenital cGVHD were retrieved retrospectively from medical
records. The global severity of each patient’s cGVHD was categorized by
combining genital and extragenital clinical scores.
Acquisition of Genital Biopsy Specimens for Histopathological
Examination
To obtain genital mucosal biopsy specimens, a 4-mm punch biopsy was
used in the vulva, and forceps biopsy specimens were performed in the
vagina. A total of 56 biopsy specimens (19 vaginal and 37 vulvar) were ob-
tained from 38 patients from areas macroscopically suspicious for cGVHD
(n ¼ 25) or from mucosa with no clinical cGVHD (n ¼ 31). To avoid sys-
tematically skewed results owing to multiple biopsy specimens, only the
ﬁrst biopsy from each patient was used for the analysis of the relationship
between clinical signs and histopathological features.
Histopathological Scoring of cGVHD
Mucosal biopsy specimens from the vulva and vagina were ﬁxed in
neutral buffered formalin and embedded in parafﬁn wax. Serial sections
were stained with hematoxylin and eosin and examined by 2 pathologists.
The histopathological criteria of Shulman et al. [14] were used to diagnose
cGVHD. A global assessment of histopathological ﬁndings for each biopsy
specimenwas performed to arrive at a ﬁnal diagnosis that was standardizedtional Study of 42 Women after HSCT
Genital cGVHD (n ¼ 22) No Genital cGVHD (n ¼ 20) P Value*
47 (26-68) 37 (19-60) .07
12 9 .80
10 11
57 (13-148) 87 (27-119) .36
12/10 8/12 .37
12/10 13/7 .54
15/7 4/16 .002
11/11 6/14 .22
4/18 8/12 .18
6/16 7/13 .74
9/13 10/10 .76
13/9 2/18 .001
17/5 9/11 .055
stem cells.
GVHD.
drome, n ¼ 3.
Figure 1. Biopsy specimens from the vulvar mucosa demonstrating normal mucosa (A), possible GVHD (B), consistent with GVHD (C), and GVHD (D). Lymphocytes
inﬁltrating the squamous epithelium (B and D) and apoptotic cell bodies (D) are evident. (Hematoxylin and eosin staining.)
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cGVHD (Figure 1). Biopsy specimens judged to be normal were classiﬁed as
no cGVHD. Biopsy specimens were classiﬁed as possible cGVHD if they
contained an inﬂammatory inﬁltrate of mostly lymphocytes, accompanied
by epithelial changes; as consistent with cGVHD if in addition to inﬂam-
mation and epithelial changes they contained a band-like inﬂammatory
inﬁltrate or apoptotic bodies; and as cGVHD if they contained both a band-
like inﬂammation and apoptotic bodies.
Statistical Analysis
Associations between different variables and genital cGVHD versus no
genital cGVHDwas tested using Fisher’s exact test for dichotomous variables
and Wilcoxon’s rank-sum test for continuous variables. Ordered categorical
variables were analyzed using a nonparametric trend test [15].
RESULTS
Study Population
Patient characteristics of the entire cohort and of the
subgroups of patients with genital cGVHD (n ¼ 22) and
without genital cGVHD (n ¼ 20) are presented in Table 1. Ten
women in the genital cGVHD group and 11 women in the no
genital cGVHD were receiving estrogen hormone replace-
ment therapy. The prevalence of cGVHD at any location was
74% (n ¼ 31) in the entire cohort. Of the background factors,
only HSCT from a sibling donor was associated with a higher
prevalence of genital cGVHD (P ¼ .002). The presence of
genital cGVHD was signiﬁcantly associated with systemic
corticosteroid treatment of extragenital cGVHD (P ¼ .001).
The prevalence of genital cGVHD was higher than that of
cGVHD at any other localization: 52%, compared with 43% for
oral, 40% for ocular, 10% for skin, 7% for lungs, and 12% for all
other. Five patients had isolated genital cGVHD.
Diagnosis of Genital cGVHD
Clinical signs consistent with the NIH criteria of genital
cGVHD were found in 22 of 42 patients (52%). Diagnostic
signs of cGVHD were observed in 21 patients, and 1 patient
with distinctive genital signs of cGVHD and extragenital
cGVHD also met the criteria for genital cGVHD (Table 2). Ofthe 21 patients with diagnostic signs, 16 had vaginal stric-
tures (in 3 cases combined with reticular white lines), and
the other 5 had lichen planuselike signs with reticular white
lines (Figure 2). cGVHD in the vagina or vulva was observed
in 14 and 5 patients, respectively, and 3 patients had cGVHD
at both locations. Two additional genital signs, vaginal
strings and teleangiectatic areas, were observed only in pa-
tients with conﬁrmed genital cGVHD (Table 2).Symptoms of Genital cGVHD
Genital symptoms reported in the questionnaire and
conﬁrmed orally at the time of diagnostic gynecologic ex-
aminations are listed in Table 3. Mucosal dryness, pain,
smarting pain, and dyspareunia were signiﬁcantly more
common in women with diagnosed genital cGVHD. Vaginal
examination was associated with marked discomfort in 5
patients, 3 of whom had partial or total vaginal stenosis.
Many women reported remitting ﬂare-ups of genital symp-
toms appearing synchronously with symptomatic cGVHD at
other locations.Clinical Scoring of Genital cGVHD
Two patients had diagnostic genital cGVHD but were
assigned a score of 0 because they reported no symptoms
and experienced no discomfort on gynecologic examination.
The other 20 patients were assigned a score of 3 (n ¼ 12), 2
(n ¼ 2), or 1 (n ¼ 6). Three patients scoring 3 had genital
signs as the sole cGVHD manifestation.Global Scoring of cGVHD
Fifteen patients (36% of all participants) had severe global
cGVHD. In 12 of these patients, this classiﬁcation was based
on a clinical score of 3 for genitals, whereas the remaining 3
patients had pulmonary disease in addition to a genital score
of 1-2 (Table 4).
Table 2
Clinical Genital Signs in Patients with and without Genital cGVHD in a Cross-Sectional Study of 42 Women after HSCT
NIH Criteria* Genital cGVHD (n ¼ 22), n No cGVHD (n ¼ 20), n P Valuey
Total Vulvar Vaginal Total Vulval Vaginal
Diagnostic signs
Synekia vaginae 12 0
Vaginal partial stenosis 5 0
Vaginal total stenosis 4 0
Reticular white lines 8 6 2 0
Distinctive signs
Synekia vulvae 4 2 .67
Fissures/ wounds 2 2 0 2 2 0 1.00
Hyperkeratotic plaque 1 1 0 0 1.00
Additional signs
Vaginal stringz 5 0 .049
Telangiectatic areasx 4 1 3 0 .11
Red and white spots{ 6 5 1 1 1 0 .096
Thin mucousa 17 16 10 11 11 1 .19
Edematous 3 2 1 0 .23
Reddened 2 2 0 1 1 1 1.00
Red spots (no white) 6 4 4 5 3 3 1.00
White spots (no red) 2 2 0 1 1 0 1.00
Dry mucosa 3 3 1 4 4 0 .69
One patient could have more than 1 sign in the vulva and/or the vagina.
* Filipovich et al.9
y Refers to “total” differences between patients with genital cGVHD and no genital cGVHD, respectively.
z A 2- to 4-mm ﬁbrotic string felt at gynecologic examination as part of the vaginal wall, not visible for the examining eye, circular, or semicircular, horizontal,
or more or less vertical and most often sore.
x The term “telangiectatic areas” is used to describe many small red vessels grouped together.
{ The red and white spots are seen together in the vulva and/or vagina, giving a mottled appearance.
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In 8 of 14 patients with diagnostic clinical cGVHD, histo-
pathological ﬁndings were consistent with or conﬁrmatory
for cGVHD (Table 5). Twenty-four biopsy specimens were
obtained from areas without clinical genital cGVHD, and in
this group, 7 specimens obtained from the vulvar mucosa
demonstrated histopathological signs consistent with
cGVHD. Four of these 7 women had diagnostic vaginal
cGVHD with stenosis and/or synechiae.
DISCUSSION
Based on the NIH criteria, 22 of the 42 women (52%) were
diagnosed with genital cGVHD, 9 of whom had partial or
total vaginal stenosis. Twelvewomen had a clinical score of 3,
indicating advanced signs and symptoms. Consequently,
genital cGVHD had a strong impact on global cGVHD cate-
gorization; in addition to the 12 women with advancedFigure 2. Vulvar cGVHD with reticular white lines.genital cGVHD, only 3 patients with pulmonary cGVHD were
classiﬁed as having severe global cGVHD. As expected, gen-
ital cGVHD was associated with marked symptoms affecting
sexual life, including dryness, pain, smarting pain, and
dyspareunia.
Despite the long duration of follow-up, a majority of pa-
tients (74%) had signs of some form of cGVHD, and indeed
36% of patients were still receiving systemic corticosteroid
treatment. There was a close association between extra-
genital and genital cGVHD. Seventeen women had both
genital and extragenital cGVHD, 5 had isolated genital
cGVHD, and 9 had only extragenital cGVHD. Two-thirds of
the patients with extragenital cGVHD had genital cGVHD as
well. Notably, of the 22 patients with genital cGVHD,13 (59%)
were receiving systemic corticosteroid therapy, with extra-
genital GVHD as the indication in all cases. Three patients
scored 3 for genital cGVHD without any extragenital cGVHD.
These data indicate that genital cGVHD should be actively
asked and looked for, not only in patients with other mani-
festations of cGVHD.
The prevalence of genital cGVHD after a long follow-up
has not been accounted for in other studies. However, Zan-
tomio et al. [11] estimated a 49% cumulative incidence of
genital cGVHD at 32 months after HSCT. In an Italian study,
the median time of onset of genital cGVHD was 7 months
after HSCT, and 25% of patients developed acute or chronic
genital GVHD up to 107 months after HSCT [9]. In another
retrospective study, Hirsch et al. [13] evaluated 138 women
who underwent HSCT between 2008 and 2010. All patients
were followed by a gynecologist from 3 months post-HSCT,
and 26 (19%) were eventually diagnosed with cGVHD based
on clinical signs or histopathological analysis. The criteria for
diagnosing genital cGVHD used in that study were not
described in detail. The higher prevalence of genital cGVHD
in our study compared with most previous studies may be
related to differences in diagnostic criteria; it is possible that
Table 3
Genital Symptoms in Patients with and without Genital cGVHD in a Cross-Sectional Study of 42 Women after HSCT
Reported Symptoms Patients with Genital cGVHD (n ¼ 22) Patients with No Genital cGVHD (n ¼ 20) P Value for Trend*
0 1 2 3 4 0 1 2 3 4
Dryness 7 1 4 5 5 14 1 2 2 1 .010
Painy 11 1 0 3 5 15 0 2 1 0 .033
Smarting pain 12 0 4 2 2 16 1 1 0 0 .028
Fissures/wounds 14 0 4 2 0 16 1 0 0 1 .16
Itching 13 2 5 1 0 15 0 3 0 0 .16
Dyspareuniaz 2 1 2 2 6 11 1 1 0 1 .001
A patient could have multiple symptoms. Symptoms were self-reported as 0, never; 1, seldom; 2, sometimes; 3, often; or 4, always.
* Refers to differences between patients with genital cGVHD and no genital cGVHD, respectively.
y With or without touching.
z Among 13 patients with genital cGVHD and 14 patients with no genital cGVHD having or attempting coitus.
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other studies.
In our patient cohort, the prevalence of genital cGVHD
was similar in patients with follow-up time under and over
the median of 80 months. The NIH criteria do not distinguish
between an ongoing inﬂammatory process and a ﬁxed
deﬁcit, however, and thus it is likely that in some women in
our study, the ﬁnding of diagnostic signs of genital cGVHD
represents an end-stage ﬁbrotic sequel rather than a pro-
gressive disease. This assumption is indirectly supported by
the lower prevalence of corticosteroid therapy (for extra-
genital cGVHD) in patients with longer than median follow-
up (4 of 21 patients versus 10 of 21 patients with shorter than
median follow-up). Consequently, it seems unlikely that our
ﬁnding of a high prevalence of severe global cGVHD, based
mainly on clinical scoring of genital cGVHD, is associated
with a signiﬁcantly reduced survival. Arai et al. [8] reported a
marked impact on survival in patients with severe global
cGVHD, but that study had a comparatively short follow-up
(18.5 months), and cGVHD severity was based on high clin-
ical scores in the eyes, mouth, and lungs.
We did encounter some difﬁculties in using the NIH
criteria for genital scoring, especially with the distinction
between scores 1 and 2, that is, mild signs and minimal
discomfort versus moderate signs and mild dyspareunia or
discomfort on gynecologic examination. Experienced
discomfort can vary depending on multiple factors, and
indeed 2 patients (with no sexual activity) scored 0 (ie, no
discomfort) on gynecologic examination despite having
diagnostic signs of vaginal cGVHD. However, this ﬁnding is
consistent with the notion that the clinical organ-relatedTable 4
Global Scoring of cGVHD in a Cross-Sectional Study of 42Women after HSCT
Clinical Diagnosis Global Score Total
None Mild Moderate Severe
Genital cGVHD, n 0 2 5 15 22
No genital cGVHD, n 11 6 3 0 20
Total 11 8 8 15 42
Scoring is based on the NIH criteria: none, no cGVHD; mild, cGVHD
involving 1 or 2 organs with a clinical score of 1; moderate, cGVHD at least 1
organ with a clinical score of 2 in any affected organ or site, or 3 organs or
sites with a clinical score of 1; severe, cGVHDwith a clinical score of 3 in any
organ or a lung score of 2.
Clinical scoring: 0, no symptoms; 1, symptomatic with mild signs on ex-
amination and no effect on coitus and minimal discomfort with gynecologic
examination; 2, symptomatic withmoderate signs on examination andmild
dyspareunia or discomfort with gynecologic examination; 3, symptomatic
with advanced signs and severe pain with coitus or inability to insert a
vaginal speculum.scoring of cGVHD should reﬂect the functional status of the
affected organ.
Two additional signs, vaginal strings and telangiectatic
areas, were observed exclusively in women with concurrent
diagnostic signs of genital cGVHD (Table 2). The ﬁnding of
vaginal strings in genital cGVHD also has been reported by
Spiryda et al. [10] and Stratton et al. [12], and telangiectatic
areas have previously been associated with genital lichen
planus [16]. In addition, red and white spots occurring
together, giving the mucous membrane a mottled appear-
ance, were seen in patients with genital cGVHD, and similar
mucosal features were described by Hirsch et al. [13]. It
seems plausible that a vaginal string heralds a ﬁbrotic cGVHD
process, and if conﬁrmed in future studies, all 3 of the fore-
going signsmight be considered diagnostic of genital cGVHD.
Our data on the relationship between clinical and histo-
pathological features of the genital mucosa must be inter-
preted with caution for several reasons. First, biopsy
specimens were obtained at the diagnostic visit were ob-
tained in only a minority of patients (18 of 42). Second, the
remaining 38 biopsy specimens were obtained sporadically
at follow-up visits in patients with or without typical clinical
genital features. In patients with clinical diagnostic cGVHD at
the location of the biopsy (n ¼ 14), the histopathological
grades were evenly distributed from 0 to 3, suggesting that
biopsy may be of limited value if the clinical diagnosis is
settled. In mucosa without clinical genital cGVHD, biopsy
specimens were more often conﬁrmative, with 17 of 24 bi-
opsy specimens graded 0-1; however, 4 of 7 patients with
positive (grade 2-3) biopsy specimens obtained from clini-
cally normal vulvar mucosa exhibited clinical diagnostic
features of vaginal cGVHD.
Our data suggest that biopsy may be indicated in patients
with genital symptoms but without diagnostic genital signs.
The presence of systemic cGVHD may widen the indication
for histopathological assessment.Table 5
Clinical Diagnosis and Histopathological Grading of First Biopsy Specimen
Obtained from the Genital Mucosa in 38 Women after HSCT*
Clinical Diagnosis Histopathological Gradey Total
0 1 2 3
cGVHD, n 3 3 5 3 14
Not cGVHD, n 6 11 7 0 24
Total 9 14 12 3 38
* From a total of 56 biopsy specimens from 38 patients; only the ﬁrst
biopsy specimen obtained from each patient is shown.
y Histopathological grading of cGVHD: 0, normal; 1, possible; 2, probable/
consistent with; 3, conﬁrmed. See text for details.
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signs, and symptoms of genital cGVHD in a cross-sectional
study using the NIH consensus criteria has revealed that
the patients’ genital symptoms had not been correctly
diagnosed by the patients’ own gynecologists and had been
treated only with hormone replacement therapy and in some
cases surgery, with poor outcomes. Our ﬁndings indicate a
high prevalence (52%) of genital cGVHD, similar to that of
ocular and oral cGVHD. The clinical signs and symptoms seen
in our cohort suggest that in a nonrelapsed cohort with a
long follow-up, the presence of genital cGVHD or its
sequellae is common and associated with serious conse-
quences for sexual life. Importantly, severe genital cGVHD
may arise in the absence of any other diagnosed cGVHD, and
even without any genital symptoms if the woman is not
having sexual intercourse. Our ﬁndings emphasize that
regardless of genital symptoms, systematic and early sur-
veillance by a gynecologist with a special interest in genital
cGVHD is important.
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